Tenet Healthcare (THC) reported Q4 earnings and guidance in line with estimates, but Cantor Fitzgerald tells investors in a research note that the selloff on the quarter seems overdone, even though there is “less to get excited about” in 2025, given policy uncertainty. The firm, which has an Overweight rating and $177 price target on the shares, does not believe there was enough clear conservatism to rally the stock given the 2024 provider group outperformance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target lowered to $161 from $190 at Barclays
- Tenet Healthcare’s Strong Financial Performance and Strategic Shift Drive Buy Rating
- Mixed Performance and Future Outlook Lead to Cautious Hold Rating for Tenet Healthcare
- Tenet Healthcare Corp. Reports Strong 2024 Results
- Morning Movers: CVS Health jumps following fourth quarter earnings